Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 23 · below the Ichimoku cloud · RSI 29 (oversold) · MACD above its signal
| 23.80 | 52-week high | +4528.55% |
| 1.50 | Previous month high | +192.69% |
| 0.6153 | R3 (classic) | +19.66% |
| 0.5818 | R2 (classic) | +13.15% |
| 0.5800 | Previous week high | +12.80% |
| 0.5483 | Previous day high | +6.63% |
| 0.5480 | R1 (classic) | +6.57% |
| 0.5145 | Pivot | +0.06% |
| 0.5142 | Price now | |
| 0.5050 | Previous month low | −1.79% |
| 0.4810 | Previous day low | −6.46% |
| 0.4807 | S1 (classic) | −6.51% |
| 0.4472 | S2 (classic) | −13.03% |
| 0.4280 | Previous week low | −16.76% |
| 0.4280 | 52-week low | −16.76% |
| 0.4134 | S3 (classic) | −19.60% |
None of the 29 investors followed here reported a position in NXTS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NXTS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 14, 2026 | Zakai ShlomoOfficer | Stock Award(Grant) at price 0.00 per share. | 51K | — |
| Oct 14, 2026 | Weiss AmitayDirector | Stock Award(Grant) at price 0.00 per share. | 101.5K | — |
| Oct 14, 2026 | Berenstein Israel YakovDirector | Stock Award(Grant) at price 0.00 per share. | 19.4K | — |
| Oct 14, 2026 | Rosenbloom RonenDirector | Stock Award(Grant) at price 0.00 per share. | 19.4K | — |
| Oct 14, 2026 | Palach DavidChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 101.5K | — |
| Oct 14, 2026 | Arbib EliahouDirector | Stock Award(Grant) at price 0.00 per share. | 19.4K | — |
| Oct 14, 2026 | Barda LitalChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 51K | — |
| Oct 14, 2026 | Sidi LiatDirector | Stock Award(Grant) at price 0.00 per share. | 14.8K | — |
| Oct 14, 2026 | Itzhaik AsafDirector | Stock Award(Grant) at price 0.00 per share. | 14.8K | — |
| Feb 8, 2026 | Zakai ShlomoOfficer | — | 50K | — |
| Feb 8, 2026 | Weiss AmitayDirector | — | 116.3K | — |
| Feb 8, 2026 | Palach DavidChief Executive Officer | — | 100K | — |
| Feb 8, 2026 | Barda LitalChief Financial Officer | — | 50K | — |
| Jan 28, 2026 | Lee Eun YoungBeneficial Owner of more than 10% of a Class of Security | Sale at price 1.36 per share. | 127 | $172 |
| May 11, 2025 | Palach DavidChief Executive Officer | — | 600K | — |
| May 11, 2025 | Barda LitalChief Financial Officer | — | 300K | — |
| Dec 22, 2024 | Weiss AmitayDirector | — | 350K | — |
| Dec 22, 2024 | Berenstein Israel YakovDirector | — | 50K | — |
| Dec 22, 2024 | Rosenbloom RonenDirector | — | 50K | — |
| Dec 22, 2024 | Arbib EliahouDirector | — | 50K | — |
TimeframesThe daily, weekly and monthly trends are down; the hourly is steadying, a bounce inside them.
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.0 | -26.0 | -29.2 | 3.2 | 17.0 | -22.8 | -60.3 | 5.3 | -22.8 | -57.9 | -12.1 | −95.6% | |
| 2025 | 412.1 | -66.1 | -44.4 | -2.1 | 13.2 | -13.2 | 3.5 | -7.6 | -51.7 | -8.9 | -10.3 | -44.7 | −80.6% |
| 2024 | -18.0 | -17.7 | -4.4 | -10.9 | -25.9 | -44.0 | 6.9 | -28.2 | -31.7 | -2.0 | -17.1 | 22.2 | −87.6% |
| 2023 | 63.4 | -10.0 | -38.7 | 10.3 | -7.2 | -14.9 | -6.1 | 5.2 | -12.6 | -36.8 | -15.9 | 5.3 | −62.2% |
| 2022 | 7.0 | 6.1 | 26.4 | -5.9 | -30.9 | -9.6 | 23.7 | -30.6 | -34.5 | -3.2 | -33.2 | -38.6 | −81.2% |
| 2021 | 42.3 | -67.3 | 275.0 | 20.0 | -41.4 | -24.9 | 19.3 | -11.1 | -23.7 | -1.9 | -0.3 | -36.0 | −53.4% |
| 2020 | 45.8 | 42.9 | 2.0 | 17.6 | -58.3 | -8.0 | 21.7 | -10.7 | -32.8 | 21.4 | 22.5 | -1.6 | +2.5% |
| 2019 | 0.0 | 300.0 | 0.0 | -60.0 | 12.5 | -89.6 | 78.6 | 0.0 | 0.0 | 1092.0 | -59.7 | 0.0 | +60.0% |
| 2018 | 44.0 | 0.0 | -30.6 | 18.0 | 0.0 | 0.0 | 0.0 | 0.0 | -40.7 | 0.0 | 0.0 | -28.6 | −50.0% |
| 2017 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 400.0 | -80.0 | 100.0 | −0.0% |
| 2016 | 0.0 | 0.0 | -50.0 | -25.0 | 0.0 | 46.7 | 27.3 | -40.0 | 7.1 | 0.0 | 0.0 | -44.4 | −75.0% |
| 2015 | -9.1 | -17.8 | 0.0 | -12.2 | -53.8 | 0.0 | -33.3 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | −59.6% |
| 2014 | 0.0 | 0.0 | 0.0 | -16.0 | 90.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.5 | −20.8% |
| 2013 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2012 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2011 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1036.4 | 0.0 | +1036.4% |
| 2010 | 0.0 | 0.0% |
No analyst coverage for this instrument.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.